Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: Report from the Cancer and Leukemia Group B

Journal of Clinical Oncology

Volumn 24, Issue 3, 2006, Pages 407-412

  Blackstock, A William ^a   Herndon II, James E ^a   Paskett, Electra D ^a   Miller, Antonius A ^a   Lathan, Christopher ^a   Niell, Harvey B ^a   Socinski, Mark A ^a   Vokes, Everett E ^a   Green, Mark R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; TOPOTECAN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; ETHNICITY; FEMALE; HUMAN; LEUKEMIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAID; METASTASIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SOCIOECONOMICS; TREATMENT OUTCOME; WEIGHT REDUCTION; AFRICAN AMERICAN; ETHNOLOGY; LUNG TUMOR; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SMALL CELL CARCINOMA; STATISTICS; SURVIVAL; UNITED STATES;

ADULT; AFRICAN AMERICANS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 33644846179     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.1436     Document Type: Article

References (39)

1. Jemal A, Murray T, Ward E, et al: Cancer Statistics 2005. CA Cancer J Clin 55:10-30, 2005
2. Reis L, Kosary C, Hankey B: SEER Cancer Statistics Review, 1973-1996. Bethesda, MD, National Cancer Institute, 1999
3. Ihde DC, Pass HI, Glatstein E: Small cell lung cancer. In: Devita VTJ, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, PA, Lippincott-Raven, 1997, pp 911-945
4. Pass HI, Mitchell JB, Johnson DH, et al: Lung Cancer. Baltimore, MD, Lippincott Williams and Wilkins, 2000
5. Gadgeel SM, Severson RK, Kau Y, et al: Impact of race in lung cancer: Analysis of temporal trends from a surveillance, epidemiology, and end results database. Chest 120:55-63, 2001
6. Stat bite: Age-adjusted lung cancer mortality rates, 1990-2000. J Natl Cancer Inst 19:731, 2004
7. Wingo PA, Ries LA, Giovino GA, et al: Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst 91:675-690, 1999
8. Ries LA, Wingo PA, Miller DS, et al: The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 88:2398-2424, 2000
9. Albain KS, Crowley JJ, LeBlanc M, et al: Determinants of improved outcome in small-cell lung cancer: An analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 8:1563-1574, 1990
10. Wingo PA, Bolden S, Tong T, et al: Cancer statistics for African Americans, 1996. CA Cancer J Clin 46:113-125, 1996
11. Young JL Jr, Ries LG, Pollack ES: Cancer patient survival among ethnic groups in the United States. J Natl Cancer Inst 73:341-352, 1984
12. Bremnes RM, Sundstrom S, Aasebo U, et al: The value of prognostic factors in small cell lung cancer: Results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer 39:303-313, 2003
13. Spiegelman D, Maurer LH, Ware JH, et al: Prognostic factors in small-cell carcinoma of the lung: An analysis of 1,521 patients. J Clin Oncol 7:344-354, 1989
14. Earle CC, Neumann PJ, Gelber RD, et al: Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol 20:1786-1792, 2002
15. Earle CC, Venditti LN, Neumann PJ, et al: Who gets chemotherapy for metastatic lung cancer? Chest 117:1239-1246, 2000
16. Greenberg ER, Chute CG, Stukel T, et al: Social and economic factors in the choice of lung cancer treatment: A population-based study in two rural states. N Engl J Med 318:612-617, 1988
17. Greenberg ER, Dain B, Freeman D, et al: Referral of lung cancer patients to university hospital cancer centers: A population-based study in two rural states. Cancer 62:1647-1652, 1988
18. Smith TJ, Penberthy L, Desch CE, et al: Differences in initial treatment patterns and outcomes of lung cancer in the elderly. Lung Cancer 13:235-252, 1995
19. Earle CC, Tsai JS, Gelber RD, et al: Effectiveness of chemotherapy for advanced lung cancer in the elderly: Instrumental variable and propensity analysis. J Clin Oncol 19:1064-1070, 2001
20. Brawley OW, Freeman HP: Race and outcomes: Is this the end of the beginning for minority health research? J Natl Cancer Inst 91:1908-1909, 1999
21. Freedman LS, Simon R, Foulkes MA, et al: Inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993: The perspective of NIH clinical trialists. Control Clin Trials 16:277-285: discussion 286-289, 293-309, 1995
22. Zelen M: Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 34:31-42, 1973
23. Naughton MJ, Herndon JE II, Shumaker SA, et al: The health-related quality of life and survival of small-cell lung cancer patients: Results of a companion study to CALGB 9033. Qual Life Res 11:235-248, 2002
24. Lyss AP, Herndon JE II, Lynch TJ Jr, et al: Novel doublets in extensive-stage small-cell lung cancer: A randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430). Clin Lung Cancer 3:205-212, 2002
25. Niell HB, Herndon JE, Miller AA, et al: Randomized phase III intergroup trial (CALGB 9732) of etoposide (VP-16) and cisplatin (DDP) with or without paclitaxel (TAX) and G-CSF in patients with extensive stage small cell lung cancer (ED-SCLC). Proc Am Soc Clin Oncol 21:293a, 2002 (abstr 1169)
26. Graziano SL, Socinski MA, Herndon JE III, et al: Dose-dense weekly paclitaxel (P) in extensive stage small cell lung cancer (ES-SCLC): Cancer and Leukemia Group B (CALGB) 39901. Proc Am Soc Clin Oncol 22:646, 2003 (abstr 2598)
27. Cox D: Regression models and life tables. J R Stat Soc 34:187-220, 1972
28. Prentice RL, Kalbfleisch JD, Peterson AV Jr, et al: The analysis of failure times in the presence of competing risks. Biometrics 34:541-554, 1978
29. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
30. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
31. Schulman KA, Berlin JA, Harless W, et al: The effect of race and sex on physicians' recommendations for cardiac catheterization. N Engl J Med 340:618-626, 1999
32. Hargraves JL, Stoddard JJ, Trude S: Minority physicians' experiences obtaining referrals to specialists and hospital admissions. MedGenMed 3:10, 2001
33. Blackstock AW, Herndon JE III, Paskett ED, et al: Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: Report from the Cancer and Leukemia Group B. J Natl Cancer Inst 94:284-290, 2002
34. McDavid K, Tucker TC, Sloggett A, et al: Cancer survival in Kentucky and health insurance coverage. Arch Intern Med 163:2135-2144, 2003
35. Murphy VH, Krumholz HM, Gross CP: Participation in clinical trials: Race-, sex-, and age-based disparities. JAMA 291:2720-2726, 2004
36. Ettinger DS, Finkelstein DM, Ritch PS, et al: Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: An Eastern Cooperative Oncology Group randomized study (E1588). Lung Cancer 37:311-318, 2002
37. Kelly K, Lovato L, Bunn PA Jr, et al: Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: A phase II trial of the Southwest Oncology Group. Clin Cancer Res 7:2325-2329, 2001
38. Chute JP, Chen T, Feigal E, et al: Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: Perceptible progress. J Clin Oncol 17:1794-1801, 1999
39. National Cancer Institute: The SEER 1973-1994 Public Use Data, SEER*Stat [computer database]. Version 1.0 for Windows 95/NT. Bethesda, MD, National Cancer Institute, 1997